Dushanbe, Tajikistan — The International Society for Stem Cell Application (ISSCA) announces its upcoming ISSCA International Certification & Conference in Regenerative Medicine – Tajikistan 2026, taking place on April 24–25, 2026, in Dushanbe, Tajikistan. This event marks a significant milestone in ISSCA’s expansion into Central Asia, a region where interest in advanced medical therapies is rapidly growing, yet access to internationally standardized education remains limited.
This initiative is the result of a strategic collaboration developed under the guidance of ISSCA Founder Benito Novas, and operationally driven by Rafael Ruiz, Commercial Director of ISSCA, in partnership with Cellgenic, ISSCA’s principal industry sponsor with active representation in Tajikistan. Together, these efforts have enabled ISSCA to establish a platform capable of generating impact not only within the country, but also across neighboring Central Asian markets.
A Collaborative Entry into an Emerging Medical Region
Rather than entering the region in isolation, ISSCA’s expansion into Tajikistan builds upon existing local momentum. By aligning global educational standards with regional leadership and infrastructure, ISSCA reinforces its role as a platform where local innovators, international experts, and responsible industry partners converge to advance regenerative medicine in a structured and sustainable way.
“Central Asia represents one of the most important frontiers for the future of regenerative medicine,” said Benito Novas, Founder of ISSCA.
“Through strategic collaboration with regional leaders and trusted partners, ISSCA is able to bring structured education, international certification, and scientific accountability to markets that are ready to grow responsibly and sustainably.”
Building a Regional Ecosystem Through Strategic Leadership
The development of ISSCA Tajikistan reflects a broader regional strategy led by Rafael Ruiz, whose focus has been on creating long-term alliances rather than one-time events.
“Our objective is not simply to host a conference, but to help establish a sustainable medical ecosystem,” said Rafael Ruiz, Commercial Director of ISSCA.
“By working closely with local partners and leveraging Cellgenic’s regional presence, we are opening access to education and certification that can benefit physicians across multiple countries in Central Asia.”
This approach positions Tajikistan as a gateway for regenerative medicine education, enabling cross-border participation and collaboration among clinicians from surrounding countries.
Scientific Focus and Clinical Education
The conference and certification programs will focus on the clinical foundations and future applications of regenerative medicine, including:
- Cellular and regenerative therapies
- Peptide-based clinical strategies
- Inflammation modulation and metabolic optimization
- Functional restoration and longevity medicine
By emphasizing evidence-based protocols and standardized education, ISSCA aims to support physicians who are beginning to integrate regenerative therapies, as well as those seeking to formalize and elevate existing clinical practices.
Connecting Physicians Beyond Borders
In addition to its academic agenda, the event will create curated environments designed to encourage meaningful professional interaction among regional physicians, international faculty, and industry experts. These spaces will allow participants to exchange clinical experiences, explore collaborative initiatives, and establish professional relationships that extend beyond national borders—an essential component for advancing medicine in geographically interconnected regions like Central Asia.
A Strategic Moment for Tajikistan and the Region
ISSCA’s arrival in Tajikistan represents a catalytic opportunity for the country and its neighbors. Supported by Cellgenic’s industry expertise and regional presence, and guided by ISSCA’s global educational framework, this initiative is expected to:
- Introduce international standards into an emerging medical market
- Support responsible clinical adoption of regenerative therapies
- Strengthen regional collaboration across Central Asia
- Empower physicians through recognized certification and training
- Position Tajikistan as a regional reference point for regenerative medicine education
Physicians and healthcare professionals interested in participating in ISSCA Tajikistan 2026 can register at:
Early registration benefits include:
- Special Early-Bird pricing
- Priority access to certification programs
- Admission to MedConnect Brasil
- Pre-event educational materials and digital resources
About ISSCA
“The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.”
About Global Stem Cells Group
“Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.”
Safe Harbor Statement
Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business, partly based on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
